Vantage logo

Covid-19 infects global drug stocks

The coronavirus pandemic wiped billions from global drug stock valuations in the first quarter, with the few gainers failing to offset huge losses elsewhere.

Vantage logo

Storm clouds gather for biotech flotations

Only seven drug developers managed to float on Western exchanges in the third quarter, and new issues in October have struggled, with Biontech the latest example.